EUVIMEDEUVIMED entdecken
Crossref

Structural optimization of tetrahydroisoquinoline-hydroxamate hybrids as potent dual ERα degraders and HDAC inhibitors

Shuangshuang Xiong, Xin Wang, Meiqi Zhu, Ke Song, Yefan Li, Jiaqi Yang, Xinyan Liu, Mofei Liu, Haijuan Dong, Mingqi Chen, Deying Chen, Hua Xiang und 1 weitere

Bioorganic Chemistry · 2023

DOI: 10.1016/j.bioorg.2023.106459 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic Chemistry, 2023. Verfasst von Shuangshuang Xiong und 12 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural Medicines, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, Ch…. Hauptthemen laut MEDLINE: Breast Neoplasms, Tetrahydroisoquinolines, Antineoplastic Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Both estrogen receptor α (ERα) and histone deacetylases (HDACs) are valid therapeutic targets for anticancer drug development. Combination therapies using diverse ERα antagonists or degraders and HDAC inhibitors have been proven effective in endocrine-resistant ER + breast cancers based on the crosstalk between ERα and HDAC pathway. In this study, we reported the optimization of a series of methoxyphenyl- or pyridinyl- substituted tetrahydroisoquinoline-hydroxamates, which were optimized from 31, a dual ERα degrader/HDAC inhibitor previously reported by our group. Most of the synthesized compounds displayed potent ERα degradation efficacy and antiproliferative activity. Among them, A04 demonstrated the best anti-proliferation activity (MCF-7 IC50 = 1.96 µM) and HDAC6 inhibitory activity (HDAC6 IC50 = 25.96 nM), which is slightly more potent than the lead compound 31 (MCF-7 IC50 = 4.38 μM, HDAC6 IC50 = 63.03 nM). In addition, compound A04 exerted ERα-independent HDAC6-inhibiting effect without agonistic activity in endometrial cells. These results demonstrated that A04 is a novel and promising dual ERα degrader/HDAC inhibitor worthy of further development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsTetrahydroisoquinolinesAntineoplastic AgentsHumansFemaleHistone Deacetylase InhibitorsEstrogen Receptor alphaHistone DeacetylasesHydroxamic AcidsCell ProliferationStructure-Activity RelationshipCell Line, Tumor

Stichwörter der Autor:innen

Breast cancerDegraderEstrogen receptorHDAC

Substanzen

Histone Deacetylase InhibitorsEstrogen Receptor alphaHistone DeacetylasesHydroxamic AcidsTetrahydroisoquinolinesAntineoplastic Agents

Autor:innen und Institutionen

  • State Key Laboratory of Natural Medicines, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
  • The Public Laboratory Platform, China Pharmaceutical University, Nanjing 210009, China.
  • State Key Laboratory of Natural Medicines, National R&D Center for Chinese Herbal Medicine Processing, College of Engineering, China Pharmaceutical University, Nanjing 211109, China.
  • Department of Analytical Chemistry, School of Science, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, China.
  • State Key Laboratory of Natural Medicines, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China. Electronic address: xianghua@cpu.edu.cn.
  • State Key Laboratory of Natural Medicines, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China. Electronic address: gsluo@cpu.edu.cn.

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Jiangsu Province

Zitieren

APA

Xiong, S., Wang, X., Zhu, M., Song, K., Li, Y., Yang, J., Liu, X., Liu, M., Dong, H., Chen, M., Chen, D., Xiang, H., & Luo, G. (2023). Structural optimization of tetrahydroisoquinoline-hydroxamate hybrids as potent dual ERα degraders and HDAC inhibitors. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2023.106459

Vancouver

Xiong S, Wang X, Zhu M, Song K, Li Y, Yang J, et al. Structural optimization of tetrahydroisoquinoline-hydroxamate hybrids as potent dual ERα degraders and HDAC inhibitors. Bioorganic Chemistry. 2023. doi:10.1016/j.bioorg.2023.106459

BibTeX
@article{Xiong2023,
  author = {Xiong, Shuangshuang and Wang, Xin and Zhu, Meiqi and Song, Ke and Li, Yefan and Yang, Jiaqi and Liu, Xinyan and Liu, Mofei and Dong, Haijuan and Chen, Mingqi and Chen, Deying and Xiang, Hua and Luo, Guoshun},
  title = {Structural optimization of tetrahydroisoquinoline-hydroxamate hybrids as potent dual ERα degraders and HDAC inhibitors},
  journal = {Bioorganic Chemistry},
  year = {2023},
  doi = {10.1016/j.bioorg.2023.106459}
}
Kostenlos starten →